Trepotec, Z., Geiger, J., Plank, C., Aneja, M
Carnitine levels in 26,462 individuals from the nationwide screening program for primary carnitine deficiency in the Faroe Islands
There is an increasing focus on the potential contributory mechanistic role of the gut microbiota in the metabolic effects of glucoregulatory and weight loss promoting drugs, including glucagon-like peptide-1 (GLP-1) receptor agonists, which have become well-established therapies in type 2 diabetes and obesity 16,17
As you lose weight on GLP-1 treatment, your BMR naturally decreases, meaning calorie requirements should be periodically reassessed
Regular GLP-1 treatment monitoring with your doctor is vital to ensure the medication is working safely and effectively for your body over the long term